Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Karolinska Invests In Swedish Firms
by Rick Mullin
January 25, 2010
| A version of this story appeared in
Volume 88, Issue 4
Karolinska Development and BioChromix, a specialist in diagnosis and monitoring of Alzheimer’s disease, have formed a company to develop novel treatments for neurogenerative disorders by leveraging BioChromix’ expertise in luminescent conjugated polymers. Karolinska will own 28% of the new company. Stockholm-based Karolinska, which specializes in commercializing academic research, has also linked up with Uminova, a private equity firm dedicated to ventures associated with Sweden’s Umeå University and other regional institutions. The two firms will study investments in start-up life sciences companies.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X